{
      "Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives as potential atypical antipsychotic agents in mice .|In research towards the development of new atypical antipsychotic agents , one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .|The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 ) is described .|Compound 7e , 5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one , from this series showed significant affinities at the 5 - HT1A and 5 - HT2A receptors and moderate affinity at the D2 receptor .|7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .": " Here are the entity relationships I extracted from the prompt:\n\n[[\"Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives\", \"in research towards\", \"development of new atypical antipsychotic agents\"],\n[\"dopaminergic system\", \"can be modulated through\", \"manipulation of the serotonergic system\"], \n[\"The synthesis and preliminary pharmacological evaluation\", \"of\", \"a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine\"],\n[\"Compound 7e\", \"showed significant affinities at\", \"the 5 - HT1A and 5 - HT2A receptors\"],\n[\"Compound 7e\", \"showed moderate affinity at\", \"the D2 receptor\"],\n[\"7e\", \"exhibits\", \"high reversal of catalepsy induced by haloperidol\"],\n[\"7e\", \"indicating its\", \"atypical antipsychotic nature\"]]",
      "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .|Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .|SNP is authorized for clinical use in USA and UK , and ATP is clinically used in other countries such as Japan .|We investigated how these two drugs act on the cardiovascular systems of 20 dogs whose hearts had been denervated by a procedure we had devised .|ATP ( 10 dogs ) or SNP ( 10 dogs ) was administered to reduce mean arterial pressure by 30 % to 70 % of control .|Before , during and after induced hypotension , we measured major cardiovascular parameters .|Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .|Cardiac output did not change .|During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .|Recoveries of heart rate and left ventricular end - diastolic pressure were not shown within 60 min after SNP had been stopped .|Both ATP and SNP should act on the pacemaker tissue of the heart .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Adenosine triphosphate (ATP)\", \"administered to\", \"patients\"], [\"sodium nitroprusside (SNP)\", \"administered to\", \"patients\"], [\"Adenosine triphosphate (ATP) and sodium nitroprusside (SNP)\", \"induce and control\", \"hypotension\"], [\"hypotension\", \"induced during\", \"anesthesia\"], [\"sodium nitroprusside (SNP)\", \"authorized for clinical use in\", \"USA and UK\"], [\"Adenosine triphosphate (ATP)\", \"clinically used in\", \"Japan and other countries\"], [\"we\", \"investigated\", \"how these two drugs act on the cardiovascular systems of 20 dogs\"], [\"20 dogs\", \"had\", \"hearts denervated\"], [\"denervation\", \"done by\", \"a procedure we had devised\"], [\"Adenosine triphosphate (ATP) or sodium nitroprusside (SNP)\", \"administered to\", \"10 dogs\"], [\"Adenosine triphosphate (ATP) or sodium nitroprusside (SNP)\", \"reduce\", \"mean arterial pressure\"], [\"we\", \"measured\", \"major cardiovascular parameters\"], [\"Hypotension induced by Adenosine triphosphate (ATP)\", \"accompanied by\", \"decreases in mean pulmonary arterial pressure, central venous pressure, left ventricular end-diastolic pressure, total peripheral resistance, rate pressure product, total body oxygen consumption, and heart rate\"], [\"Cardiac output\", \"did not change during\", \"Hypotension induced by Adenosine triphosphate (ATP)\"], [\"similar decreases\", \"observed during\", \"hypotension produced by sodium nitroprusside (SNP)\"], [\"heart rate and cardiac output\", \"increased during\", \"hypotension produced by sodium nitroprusside (SNP)\"], [\"recoveries of heart rate and left ventricular end-diastolic pressure\", \"not shown\", \"within 60 min after sodium nitroprusside (SNP) had been stopped\"], [\"Both Adenosine triphosphate (ATP) and sodium nitroprusside (SNP)\", \"should act on\", \"the pacemaker tissue of the heart\"]]",
      "Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .|Hemodynamic effects and histamine release by bolus injection of 0 . 35 mg / kg of d - tubocurarine were studied in 24 patients .|H1 - and H2 - histamine antagonists or placebo were given before dosing with d - tubocurarine in a randomized double - blind fashion to four groups : group 1 - - placebo ; group 2 - - cimetidine , 4 mg / kg , plus placebo ; group 3 - - chlorpheniramine , 0 . 1 mg / kg , plus placebo ; and group 4 - - cimetidine plus chlorpheniramine .|Histamine release occurred in most patients , the highest level 2 minutes after d - tubocurarine dosing .|Group 1 had a moderate negative correlation between plasma histamine change and systemic vascular resistance ( r = 0 . 58 ; P less than 0 . 05 ) not present in group 4 .|Prior dosing with antagonists partially prevented the fall in systemic vascular resistance .|These data demonstrate that the hemodynamic changes associated with d - tubocurarine dosing are only partially explained by histamine release .|Thus prior dosing with H1 - and H2 - antagonists provides only partial protection .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Histamine antagonists\", \"and\", \"d - tubocurarine - induced hypotension\"], \n[\"Hemodynamic effects\", \"and\", \"histamine release\"], \n[\"bolus injection\", \"of\", \"0 . 35 mg / kg of d - tubocurarine\"], \n[\"24 patients\", \"\", \"studied\"],\n[\"H1 - and H2 - histamine antagonists\", \"or\", \"placebo\"], \n[\"given\", \"before dosing with\", \"d - tubocurarine\"], \n[\"four groups\", \"\", \"\"],\n[\"group 1\", \"-\", \"placebo\"],\n[\"group 2\", \"-\", \"cimetidine , 4 mg / kg , plus placebo\"],\n[\"group 3\", \"-\", \"chlorpheniramine , 0 . 1 mg / kg , plus placebo\"], \n[\"group 4\", \"-\", \"cimetidine plus chlorpheniramine\"],\n[\"Histamine release\", \"occurred in\", \"most patients\"],  \n[\"\", \"the highest level\", \"2 minutes after d - tubocurarine dosing\"],\n[\"Group 1\", \"had\", \"a moderate negative correlation between plasma histamine change and systemic vascular resistance\"],\n[\"systemic vascular resistance\", \"\", \"r = 0 . 58 ; P less than 0 . 05\"], \n[\"group 4\", \"\", \"not present in\"],\n[\"Prior dosing\", \"with\", \"antagonists\"],\n[\"the fall\", \"in\", \"systemic vascular resistance\"],\n[\"partially prevented\", \"\", \"\"],\n[\"These data\", \"demonstrate\", \"the hemodynamic changes associated with d - tubocurarine dosing\"], \n[\"only partially explained by\", \"are\", \"histamine release\"],\n[\"Thus prior dosing\", \"with\", \"H1 - and H2 - antagonists\"],\n[\"only partial protection\", \"provides\", \"\"]]\n\nThe key entities I identified were:\n- Histamine antagonists, d-tubocurarine, hemodynamic effects, histamine release\n- Patients, groups 1-4, placebo, cimetidine, chlorpheniramine \n- Systemic vascular resistance, plasma histamine change\n- Prior dosing with antagonists\n\nAnd the key relationships between them around the hemodynamic effects and histamine release caused by d-tubocurarine and how prior dosing with antagonists provides only partial protection.",
      "Cholecystokinin - octapeptide restored morphine - induced hippocampal long - term potentiation impairment in rats .|Cholecystokinin - octapeptide ( CCK - 8 ) , which is a typical brain - gut peptide , exerts a wide range of biological activities on the central nervous system .|We have previously reported that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals .|Here , we investigated the effects of CCK - 8 on long - term potentiation ( LTP ) in the lateral perforant path ( LPP ) - granule cell synapse of rat dentate gyrus ( DG ) in acute saline or morphine - treated rats .|Population spikes ( PS ) , which were evoked by stimulation of the LPP , were recorded in the DG region .|Acute morphine ( 30mg / kg , s . c . ) treatment significantly attenuated hippocampal LTP and CCK - 8 ( 1ug , i . c . v . ) restored the amplitude of PS that was attenuated by morphine injection .|Furthermore , microinjection of CCK - 8 ( 0 . 1 and 1ug , i . c . v . ) also significantly augmented hippocampal LTP in saline - treated ( 1ml / kg , s . c . ) rats .|Pre - treatment of the CCK2 receptor antagonist L - 365 , 260 ( 10ug , i . c . v ) reversed the effects of CCK - 8 , but the CCK1 receptor antagonist L - 364 , 718 ( 10ug , i . c . v ) did not .|The present results demonstrate that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK - 8 on morphine - induced memory impairment .": " Here are the extracted relationships from the prompt:\n\n[[\"Cholecystokinin - octapeptide\", \"restored\", \"morphine - induced hippocampal long - term potentiation impairment in rats\"], [\"Cholecystokinin - octapeptide (CCK - 8)\", \"is\", \"a typical brain - gut peptide\"], [\"Cholecystokinin - octapeptide (CCK - 8)\", \"exerts\", \"a wide range of biological activities\"], [\"Cholecystokinin - octapeptide (CCK - 8)\", \"exerts activities on\", \"the central nervous system\"], [\"We\", \"have previously reported\", \"that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals\"], [\"Here\", \"investigated\", \"the effects of CCK - 8 on long - term potentiation (LTP) in the lateral perforant path (LPP) - granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine - treated rats\"], [\"Population spikes (PS)\", \"were evoked by\", \"stimulation of the LPP\"], [\"Population spikes (PS)\", \"were recorded in\", \"the DG region\"], [\"Acute morphine (30mg / kg, s.c.) treatment\", \"significantly attenuated\", \"hippocampal LTP\"], [\"CCK - 8 (1ug, i.c.v.)\", \"restored\", \"the amplitude of PS that was attenuated by morphine injection\"], [\"microinjection of CCK - 8 (0.1 and 1ug, i.c.v.)\", \"significantly augmented\", \"hippocampal LTP in saline - treated (1ml / kg, s.c.) rats\"], [\"Pre - treatment of the CCK2 receptor antagonist L - 365, 260 (10ug, i.c.v)\", \"reversed\", \"the effects of CCK - 8\"], [\"the CCK1 receptor antagonist L - 364, 718 (10ug, i.c.v)\", \"did not reverse\", \"the effects of CCK - 8\"], [\"The present results\", \"demonstrate\", \"that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors\"], [\"The present results\", \"suggest\", \"an ameliorative function of CCK - 8 on morphine - induced memory impairment\"]]",
      "Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .|Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .|When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .|In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .|This developed a median of 9 days after initiation of high - dose etoposide therapy .|Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .|These abnormalities resolved rapidly after initiation of high - dose intravenous dexamethasone therapy .|In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .|This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Etoposide (VP-16-213)\", \"has been used in the treatment of\", \"many solid tumors and hematologic malignancies\"], [\"Etoposide (VP-16-213)\", \"has activity against\", \"several treatment-resistant cancers including malignant glioma\"], [\"high doses and in conjunction with autologous bone marrow transplantation\", \"increases activity of\", \"Etoposide (VP-16-213)\"], [\"sudden severe neurologic deterioration\", \"occurred in\", \"six of eight patients\"], [\"sudden severe neurologic deterioration\", \"developed a median of 9 days after\", \"initiation of high-dose etoposide therapy\"], [\"Significant clinical manifestations\", \"have included\", \"confusion\"], [\"Significant clinical manifestations\", \"have included\", \"papilledema\"], [\"Significant clinical manifestations\", \"have included\", \"somnolence\"], [\"Significant clinical manifestations\", \"have included\", \"exacerbation of motor deficits\"], [\"Significant clinical manifestations\", \"have included\", \" sharp increase in seizure activity\"], [\"these abnormalities\", \"resolved rapidly after\", \"initiation of high-dose intravenous dexamethasone therapy\"], [\"computerized tomographic (CT) brain scans\", \"demonstrated\", \"stability in tumor size and peritumor edema\"], [\"computerized tomographic (CT) brain scans\", \"compared with\", \"pretransplant scans\"], [\"This complication\", \"appears to represent\", \"a significant new toxicity of high-dose etoposide therapy for malignant glioma\"]]",
      "Increased anxiogenic effects of caffeine in panic disorders .|The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .|Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .|In the patients , but not the healthy subjects , these symptoms were significantly correlated with plasma caffeine levels .|Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .|Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients .|Caffeine increased plasma cortisol levels equally in the patient and healthy groups .|Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .|Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .": " Based on the prompt, here are the extracted relations:\n\n[[\"caffeine\", \"has\", \"anxiogenic effects\"], [\"anxiogenic effects of caffeine\", \"increased in\", \"panic disorders\"], [\"caffeine\", \"is\", \"adenosine receptor antagonist\"], [\"caffeine\", \"produces\", \"greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors\"], [\"greater increases in symptoms\", \"in\", \"the patients compared with healthy subjects\"], [\"symptoms\", \"significantly correlated with\", \"plasma caffeine levels\"], [\"caffeine\", \"did not alter\", \"plasma MHPG levels\"], [\"caffeine\", \"increased\", \"plasma cortisol levels\"], [\"increased plasma cortisol levels\", \"equally in\", \"the patient and healthy groups\"], [\"some panic disorder patients\", \"may have\", \"abnormalities in neuronal systems involving adenosine\"], [\"Patients with anxiety disorders\", \"may benefit by avoiding\", \"caffeine-containing foods and beverages\"]]",
      "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .|The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .|Rats were divided into three groups : sham , VCM and VCM plus erdosteine .|VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .|Erdosteine was administered orally .|VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .|Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .|Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .|There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .|Erdosteine caused a marked reduction in the extent of tubular damage .|It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"vancomycin\", \"induces\", \"oxidative stress\"], [\"vancomycin\", \"promotes production of\", \"reactive oxygen species (ROS)\"], [\"oxidative stress\", \"plays role in pathogenesis of\", \"vancomycin-induced nephrotoxicity\"], [\"erdosteine\", \"has\", \"antioxidant properties\"], [\"erdosteine\", \"protects\", \"kidney tissue\"], [\"erdosteine\", \"protects against\", \"vancomycin-induced renal impairment\"], [\"rats\", \"divided into\", \"sham group\"], [\"rats\", \"divided into\", \"VCM group\"], [\"rats\", \"divided into\", \"VCM plus erdosteine group\"], [\"vancomycin\", \"administrated intraperitoneally to\", \"rats\"], [\"erdosteine\", \"administered orally to\", \"rats\"], [\"vancomycin administration\", \"increases\", \"renal malondialdehyde (MDA)\"], [\"vancomycin administration\", \"increases\", \"urinary N-acetyl-beta-d-glucosaminidase (NAG) excretion\"], [\"N-acetyl-beta-d-glucosaminidase (NAG)\", \"marker of\", \"renal tubular injury\"], [\"vancomycin administration\", \"decreases\", \"superoxide dismutase (SOD)\"], [\"vancomycin administration\", \"decreases\", \"catalase (CAT)\"], [\"erdosteine administration\", \"decreases\", \"renal malondialdehyde (MDA)\"], [\"erdosteine administration\", \"decreases\", \"urinary N-acetyl-beta-d-glucosaminidase (NAG) excretion\"], [\"erdosteine administration\", \"increases\", \"superoxide dismutase (SOD) activity\"], [\"vancomycin\", \"induces\", \"nephrotoxicity\"], [\"oxidative tubular damage\", \"plays role in\", \"vancomycin-induced nephrotoxicity\"], [\"modulation of oxidative stress\", \"reduces\", \"vancomycin-induced kidney damage\"]]",
      "Comparison of laryngeal mask with endotracheal tube for anesthesia in endoscopic sinus surgery .|BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v .|anesthesia ( TIVA ) .|METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .|Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .|RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .|CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .": " Here are the relations I extracted from the given prompt:\n\n[[\"laryngeal mask\", \"compared with\", \"endotracheal tube\"], [\"laryngeal mask\", \"provides\", \"better surgical conditions\"], [\"laryngeal mask\", \"allows for\", \"induced hypotension with low doses of remifentanil during TIVA\"], [\"laryngeal mask\", \"used during\", \"controlled hypotension anesthesia\"], [\"study\", \"purpose of\", \"compare surgical conditions including amount of intraoperative bleeding, intraoperative blood pressure during FESS using laryngeal mask versus endotracheal tube\"], [\"laryngeal mask\", \"using\", \"lower rates of remifentanil infusion\"], [\"laryngeal mask\", \"using\", \"lower total dose of remifentanil\"], [\"controlled hypotension\", \"achieved within shorter period using\", \"laryngeal mask\"]]",
      "Paclitaxel 3 - hour infusion given alone and combined with carboplatin : preliminary results of dose - escalation trials .|Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .|Carboplatin was given at a fixed target area under the concentration - time curve of 6 . 0 by the Calvert formula , whereas paclitaxel was escalated in patient cohorts from 150 mg / m2 ( dose level I ) to 175 , 200 , 225 , and 250 mg / m2 .|The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .|Therapeutic effects were noted at all dose levels , with objective responses in 17 ( two complete and 15 partial regressions ) of 41 previously untreated patients .|Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .|Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Paclitaxel\", \"given by\", \"3 - hour infusion\"],\n[\"Paclitaxel\", \"combined with\", \"carboplatin\"], \n[\"Carboplatin\", \"given at\", \"fixed target area under the concentration - time curve of 6.0\"],\n[\"Carboplatin\", \"given by\", \"Calvert formula\"],\n[\"paclitaxel\", \"escalated from\", \"150 mg / m2\"],\n[\"paclitaxel\", \"escalated to\", \"175 mg / m2\"], \n[\"paclitaxel\", \"escalated to\", \"200 mg / m2\"],\n[\"paclitaxel\", \"escalated to\", \"225 mg / m2\"], \n[\"paclitaxel\", \"escalated to\", \"250 mg / m2\"],\n[\"225 mg / m2 paclitaxel\", \"expanded for\", \"phase II study\"],  \n[\"250 mg / m2 paclitaxel\", \"required modification because of\", \"nonhematologic toxicities\"],\n[\"nonhematologic toxicities\", \"included\", \"arthralgia\"],\n[\"nonhematologic toxicities\", \"included\", \"sensory neuropathy\"],\n[\"Therapeutic effects\", \"noted at\", \"all dose levels\"],\n[\"Objective responses seen in\", \"number of patients\", \"17\"],\n[\"Objective responses seen in\", \"type of patients\",\"previously untreated patients\"], \n[\"Toxicities\", \"compared with\", \"cohort of patients in a phase I trial of paclitaxel alone\"], \n[\"carboplatin\", \"did not appear to add to\", \"the hematologic toxicities\"],\n[\"paclitaxel / carboplatin combination\", \"could be dosed every\", \"3 weeks\"]]",
      "Quinine - induced arrhythmia in a patient with severe malaria .|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .|A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .|The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .|On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .|On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .|He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .|Quinine infusion was discontinued and changed with sulfate quinine tablets .|Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .|He was discharged on 7th day in good condition .|Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .|Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .": " Based on the prompt, here are the extracted entity relationships:\n\n[[\"Quinine\", \"induced\", \"arrhythmia\"], [\"arrhythmia\", \"in\", \"a patient with severe malaria\"], [\"there\", \"was\", \"a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion\"], [\"A man, 25 years old,\", \"was admitted\", \"to hospital\"], [\"The patient\", \"was\", \"fully conscious\"], [\"The patient\", \"had\", \"blood pressure 120 / 80 mmHg\"], [\"The patient\", \"had\", \"pulse rate 100 x / minute\"], [\"The patient\", \"had\", \"regular\" , \"pulse rate\"], [\"On admission\", \"laboratory examination showed\", \"Plasmodium falciparum (++++)\"], [\"On admission\", \"laboratory examination showed\", \"total bilirubin 8.25 mg/dL\"], [\"On admission\", \"laboratory examination showed\", \"conjugated bilirubin 4.36 mg/dL\"], [\"On admission\", \"laboratory examination showed\", \"unconjugated bilirubin 3.89 mg/dL\"], [\"On admission\", \"laboratory examination showed\", \"potassium 3.52 meq/L\"], [\"Patient\", \"was diagnosed as\", \"severe malaria with jaundice\"], [\"Patient\", \"got\", \"quinine infusion in dextrose 5% 500 mg / 8 hour\"], [\"On the second day\", \"the patient had\", \"vomitus\"], [\"On the second day\", \"the patient had\", \"diarrhea\"], [\"On the second day\", \"the patient had\", \"tinnitus\"], [\"On the second day\", \"the patient had\", \"loss of hearing\"], [\"After 30 hours of quinine infusion\", \"the patient felt\", \"palpitation\"], [\"electrocardiography (ECG) recording\", \"showed\", \"premature ventricular contraction (PVC) > 5 x /minute\"], [\"electrocardiography (ECG) recording\", \"showed\", \"trigemini\"], [\"electrocardiography (ECG) recording\", \"showed\", \"constant type -- sinoatrial block\"], [\"electrocardiography (ECG) recording\", \"showed\", \"positive U wave\"], [\"He\", \"was treated with\", \"lidocaine 50 mg intravenously\"], [\"He\", \"was treated with\", \"infusion 1500 mg in dextrose 5% / 24 hour\"], [\"He\", \"was treated with\", \"potassium aspartate tablet\"], [\"Quinine infusion\", \"was discontinued\"], [\"Quinine infusion\", \"was changed with\", \"sulfate quinine tablets\"], [\"Three hours later\", \"the patient felt\", \"better\"], [\"the frequency of PVC\", \"reduced to\", \"4 - 5 x /minute\"], [\"on the third day\", \"ECG was\", \"normal\"], [\"on the third day\", \"potassium level was\", \"3.34 meq/L\"], [\"He\", \"was discharged\", \"on 7th day\"], [\"He\", \"was discharged\", \"in good condition\"], [\"Quinine, like quinidine,\", \"is\", \"a chincona alkaloid that has anti-arrhythmic property\"], [\"it\", \"also\", \"pro - arrhythmic\"], [\"it\", \"can cause\", \"various arrhythmias, including severe arrhythmia such as multiple PVC\"], [\"Administration of parenteral quinine\", \"must be done\", \"carefully and with good observation\"], [\"its pro - arrhythmic effect\", \"can cause\", \"various arrhythmias\"], [\"its pro - arrhythmic effect\", \"can cause\", \"severe arrhythmia\"], [\"its pro - arrhythmic effect\", \"occurs especially in\", \"older patients who have heart diseases\"], [\"its pro - arrhythmic effect\", \"occurs especially in\", \"patients with electrolyte disorder (hypokalemia)\"], [\"electrolyte disorder (hypokalemia)\", \"frequently occurs\", \"due to vomiting and or diarrhea in malaria cases\"]]",
      "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .|Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .|This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .|Pregnant Wistar rats were assigned to five groups : intact - control , saline - control , melatonin - treated , BCNU - exposed and BCNU - exposed plus melatonin .|Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery .|Immuno / histochemistry and electron microscopy were carried out on the offspring cerebellum , and levels of malondialdehyde and superoxide dismutase were determined .|Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .|There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU - exposed group , but a decreased immunoreactivity to glial fibrillary acidic protein , synaptophysin and transforming growth factor beta1 was observed , indicating a delayed maturation , and melatonin significantly reversed these changes .|Malondialdehyde level in BCNU - exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group ( P < 0 . 01 ) , while there were no significant differences in the superoxide dismutase levels between these groups .|These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"cortical dysplasia\", \"is characterized by\", \"defects in proliferation, migration and maturation\"], [\"cortical dysplasia\", \"induced by\", \"maternal exposure to carmustine\"], [\"carmustine\", \"also known as\", \"[1,3-bis(2-chloroethyl)-1-nitrosourea] (BCNU)\"], [\"BCNU\", \"given on\", \"embryonic day 15\"], [\"melatonin\", \"given until\", \"delivery\"], [\"BCNU exposure\", \"leads to\", \"delayed maturation of offspring cerebellum\"], [\"melatonin\", \"protects against effects of\", \"BCNU\"], [\"BCNU exposure\", \"increases\", \"number of TUNEL positive cells\"], [\"BCNU exposure\", \"increases\", \"number of nestin positive cells\"], [\"BCNU exposure\", \"decreases\", \"immunoreactivity to glial fibrillary acidic protein\"], [\"BCNU exposure\", \"decreases\", \"immunoreactivity to synaptophysin\"], [\"BCNU exposure\", \"decreases\", \"immunoreactivity to transforming growth factor beta1\"], [\"BCNU exposure\", \"indicates\", \"delayed maturation\"], [\"BCNU exposure\", \"increases\", \"malondialdehyde level\"], [\"melatonin\", \"decreases\", \"malondialdehyde levels in BCNU group\"], [\"BCNU exposure\", \"no effect on\", \"superoxide dismutase levels\"], [\"melatonin\", \"no effect on\", \"superoxide dismutase levels\"]]",
      "Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .|The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .|We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .|Immunocytochemistry confirmed expression of h - SOD1 in inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice .|Transgenic and nontransgenic littermates received kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth .|Auditory thresholds were tested by evoked auditory brain stem responses at 1 month after birth .|In nontransgenic animals , the threshold in the kanamycin - treated group was 45 - 50 dB higher than in saline - injected controls .|In the transgenic group , kanamycin increased the threshold by only 15 dB over the respective controls .|The effects were similar at 12 and 24 kHz .|The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .|The results also suggest transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention .": " Here are the relationships extracted from the given prompt:\n\n[[\"Overexpression of copper / zinc - superoxide dismutase\", \"protects from\", \"kanamycin - induced hearing loss\"], [\"reactive oxygen species\", \"play role in\", \"aminoglycoside - induced ototoxicity\"], [\"aminoglycoside - iron complexes\", \"catalyze formation of\", \"superoxide radicals\"], [\"antioxidants\", \"attenuate\", \"ototoxicity\"], [\"Cu / Zn - superoxide dismutase ( h - SOD1 )\", \"should protect\", \"transgenic mice from ototoxicity\"], [\"h - SOD1\", \"expressed in\", \"inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice\"], [\"kanamycin\", \"given to\", \"transgenic and nontransgenic littermates\"], [\"Auditory thresholds\", \"tested by\", \"evoked auditory brain stem responses\"], [\"kanamycin\", \"increased threshold by 45 - 50 dB in\", \"nontransgenic animals\"], [\"kanamycin\", \"increased threshold by only 15 dB in\", \"the transgenic group\"], [\"effects of kanamycin\", \"were similar at\", \"12 and 24 kHz\"], [\"overexpression of superoxide dismutase\", \"supports\", \"oxidant stress plays a significant role in aminoglycoside - induced ototoxicity\"], [\"transgenic animals\", \"as suitable models to investigate\", \"underlying mechanisms and possible strategies for prevention\"]]",
      "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .|Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .|We performed a single - blind , placebo - controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen ( HBsAg ) carriers .|Forty - two Chinese HBsAg carriers were randomized to receive placebo ( 6 patients ) or lamivudine orally in dosages of 25 mg , 100 mg , or 300 mg daily ( 12 patients for each dosage ) .|The drug was given for 4 weeks .|The patients were closely monitored clinically , biochemically , and serologically up to 4 weeks after drug treatment .|All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .|Although 25 mg of lamivudine was slightly less effective than 100 mg ( P = . 011 ) and 300 mg ( P = . 005 ) , it still induced 94 % suppression of HBV DNA after the fourth week of therapy .|HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy .|There was no change in the hepatitis B e antigen status or in aminotransferase levels .|No serious adverse events were observed .|In conclusion , a 4 - week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers .|The suppression was > 90 % but reversible .|Studies with long - term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Lamivudine\", \"is\", \"a novel 2',3'-dideoxy cytosine analogue\"], [\"Lamivudine\", \"has\", \"potent inhibitory effects on hepatitis B virus replication in vitro and in vivo\"], [\"We\", \"performed\", \"a single-blind, placebo-controlled study\"], [\"study\", \"to assess\", \"its effectiveness and safety in Chinese hepatitis B surface antigen (HBsAg) carriers\"], [\"Forty-two Chinese HBsAg carriers\", \"were randomized\", \"to receive placebo (6 patients) or lamivudine orally in dosages of 25 mg, 100 mg, or 300 mg daily (12 patients for each dosage)\"], [\"The drug\", \"was given\", \"for 4 weeks\"], [\"patients\", \"were monitored\", \"clinically, biochemically, and serologically up to 4 weeks after drug treatment \"], [\"All 36 patients receiving lamivudine\", \"had\", \"a decrease in hepatitis B virus (HBV) DNA values of > 90%\"], [\"decrease in hepatitis B virus (HBV) DNA values\", \"compared with\", \"placebo\"], [\"25 mg of lamivudine \", \"was\", \"slightly less effective than 100 mg and 300 mg\"], [\"it\", \"still induced\", \"94% suppression of HBV DNA after the fourth week of therapy\"], [\"HBV DNA values\", \"returned\", \"to pretreatment levels within 4 weeks of cessation of therapy\"], [\"There\", \"was\", \"no change in the hepatitis B e antigen status or in aminotransferase levels\"], [\"No serious adverse events\", \"were observed\", \" \"], [\"a 4-week course of lamivudine\", \"was\", \"safe and effective in suppression of HBV DNA in Chinese HBsAg carriers\"], [\"The suppression\", \"was\", \"> 90% but reversible\"], [\"Studies with long-term lamivudine administration\", \"should be performed\", \"to determine if prolonged suppression of HBV DNA can be achieved\"]]",
      "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane .|A 69 - year - old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis .|Massive bleeding appeared during surgery which lasted for six hours .|Postoperative evolution under supportive therapy was favourable .|Complete recovery was confirmed by repeated controls performed over a period of one year after surgery .": " Based on the prompt, I identified the following entity relationships:\n\n[[\"A 69 - year - old man\", \"operated for\", \"acute cholecystitis\"], [\"acute cholecystitis\", \"under\", \"methoxyflurane anesthesia\"], [\"A 69 - year - old man\", \"developed\", \"hepatic insufficiency syndrome\"], [\"A 69 - year - old man\", \"developed\", \"renal tubular acidosis\"], [\"Massive bleeding\", \"appeared during\", \"surgery\"], [\"surgery\", \"lasted for\", \"six hours\"], [\"A 69 - year - old man\", \"under\", \"supportive therapy\"], [\"evolution\", \"was\", \"favourable\"], [\"Complete recovery\", \"was confirmed by\", \"repeated controls\"], [\"repeated controls\", \"performed over\", \"period of one year after surgery\"]]",
      "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine - induced hypotension and bradycardia .|The effects of microinjection of clonidine ( 1 - 10 micrograms in 1 microliter ) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in urethane - anesthetized rats .|Intramedullary administration of clonidine , but not saline vehicle , caused a dose - dependent decrease in both the mean arterial pressure and the heart rate .|The clonidine - induced hypotension was antagonized by prior spinal transection , but not bilateral vagotomy .|On the other hand , the clonidine - induced bradycardia was antagonized by prior bilateral vagotomy , but not spinal transection .|Furthermore , selective destruction of the spinal 5 - HT nerves , produced by bilateral spinal injection of 5 , 7 - dihydroxytryptamine , reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats .|The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia .|The induced hypotension is brought about by a decrease in sympathetic efferent activity , whereas the induced bradycardia was due to an increase in vagal efferent activity .": " Here are the extracted relationships from the prompt:\n\n[[\"clonidine\", \"microinjected into\", \"region adjacent to ventrolateral surface of medulla oblongata\"], [\"microinjection of clonidine\", \"causes\", \"decrease in mean arterial pressure\"], [\"microinjection of clonidine\", \"causes\", \"decrease in heart rate\"], [\"clonidine-induced hypotension\", \"antagonized by\", \"prior spinal transection\"], [\"clonidine-induced hypotension\", \"not antagonized by\", \"bilateral vagotomy\"], [\"clonidine-induced bradycardia\", \"antagonized by\", \"prior bilateral vagotomy\"], [\"clonidine-induced bradycardia\", \"not antagonized by\", \"spinal transection\"], [\"destruction of spinal 5-HT nerves\", \"reduces\", \"magnitude of vasodepressor or bradycardiac responses to clonidine\"], [\"bulbospinal serotonergic pathway\", \"involved in\", \"development of clonidine-induced hypotension\"], [\"bulbospinal serotonergic pathway\", \"involved in\", \"development of clonidine-induced bradycardia\"], [\"induced hypotension\", \"brought about by\", \"decrease in sympathetic efferent activity\"], [\"induced bradycardia\", \"brought about by\", \"increase in vagal efferent activity\"]]",
      "Treatment - related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter .|This report describes unique contrast enhancement of the white matter on T1 - weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy , which developed from acute lymphoblastic leukemia treated with high - dose methotrexate .|In both patients , the enhancement was more pronounced near the base of the brain than at the vertex .|Necropsy of the first case revealed loss of myelination and necrosis of the white matter .|Possible mechanisms causing such a leukoencephalopathy are discussed .": " Based on the prompt, I extracted the following entity relationships:\n\n[[\"disseminated necrotizing leukoencephalopathy\", \"developed from\", \"acute lymphoblastic leukemia treated with high - dose methotrexate\"], [\"disseminated necrotizing leukoencephalopathy\", \"has\", \"characteristic contrast enhancement of the white matter\"], [\"contrast enhancement of the white matter\", \"more pronounced near\", \"the base of the brain than at the vertex\"], [\"first case\", \"revealed\", \"loss of myelination and necrosis of the white matter\"]]",
      "Oxidative damage precedes nitrative damage in adriamycin - induced cardiac mitochondrial injury .|The purpose of the present study was to determine if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage , and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach .|B6C3 mice were treated with a single dose of 20 mg / kg ADR .|Ultrastructural damage and levels of 4 - hydroxy - 2 - nonenal ( 4HNE ) - protein adducts and 3 - nitrotyrosine ( 3NT ) were analyzed .|Quantitative ultrastructural damage using computerized image techniques showed cardiomyocyte injury as early as 3 hours , with mitochondria being the most extensively and progressively injured subcellular organelle .|Analysis of 4HNE protein adducts by immunogold electron microscopy showed appearance of 4HNE protein adducts in mitochondria as early as 3 hours , with a peak at 6 hours and subsequent decline at 24 hours .|3NT levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours .|Our data showed ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared .|These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage .|The progressive nature of mitochondrial injury suggests that mitochondria , not other subcellular organelles , are the major site of intracellular injury .": " Here are the relationships I extracted from the prompt:\n\n[[\"Oxidative damage\", \"precedes\", \"nitrative damage\"], [\"oxidative damage\", \"in\", \"adriamycin - induced cardiac mitochondrial injury\"], [\"The purpose of the present study\", \"was to determine\", \"if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage\"], [\"The purpose of the present study\", \"was to determine\", \"to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach\"], [\"B6C3 mice\", \"were treated with\", \"a single dose of 20 mg / kg ADR\"], [\"Ultrastructural damage and levels of 4 - hydroxy - 2 - nonenal ( 4HNE ) - protein adducts and 3 - nitrotyrosine ( 3NT)\", \"were analyzed\"], [\"Quantitative ultrastructural damage using computerized image techniques\", \"showed\", \"cardiomyocyte injury as early as 3 hours\"], [\"mitochondria\", \"being\", \"the most extensively and progressively injured subcellular organelle\"], [\"Analysis of 4HNE protein adducts by immunogold electron microscopy\", \"showed\", \"appearance of 4HNE protein adducts in mitochondria as early as 3 hours\"], [\"4HNE - protein adducts in mitochondria\", \"had\", \"a peak at 6 hours and subsequent decline at 24 hours\"], [\"3NT levels\", \"were significantly increased\", \"in all subcellular compartments at 6 hours\"], [\"3NT levels\", \"subsequently declined\", \"at 24 hours\"], [\"Our data\", \"showed\", \"ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared\"], [\"These results\", \"document for the first time in vivo\", \"that mitochondrial oxidative damage precedes nitrative damage\"], [\"The progressive nature of mitochondrial injury\", \"suggests\", \"that mitochondria , not other subcellular organelles , are the major site of intracellular injury\"]]",
      "Ifosfamide related encephalopathy : the need for a timely EEG evaluation .|BACKGROUND : Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas , lymphoma , gynecologic and testicular cancers .|Encephalopathy has been reported in 10 - 40 % of patients receiving high - dose IV ifosfamide .|OBJECTIVE : To highlight the role of electroencephalogram ( EEG ) in the early detection and management of ifosfamide related encephalopathy .|METHODS : Retrospective chart review including clinical data and EEG recordings was done on five patients , admitted to MD Anderson Cancer Center between years 2009 and 2012 , who developed ifosfamide related acute encephalopathy .|RESULTS : All five patients experienced symptoms of encephalopathy soon after ( within 12 h - 2 days ) receiving ifosfamide .|Two patients developed generalized convulsions while one patient developed continuous non - convulsive status epilepticus ( NCSE ) that required ICU admission and intubation .|Initial EEG showed epileptiform discharges in three patients ; run of triphasic waves in one patient and moderate degree diffuse generalized slowing .|Mixed pattern with the presence of both sharps and triphasic waves were also noted .|Repeat EEGs within 24_h of symptom onset showed marked improvement that was correlated with clinical improvement .|CONCLUSIONS : Severity of ifosfamide related encephalopathy correlates with EEG changes .|We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy .": " Based on the prompt, I identified the following entity relationships:\n\n[[\"Ifosfamide\", \"is\", \"an alkylating agent\"], [\"Ifosfamide\", \"useful in treatment of\", \"sarcomas\"], [\"Ifosfamide\", \"useful in treatment of \", \"lymphoma\"], [\"Ifosfamide\", \"useful in treatment of\", \"gynecologic cancers\"], [\"Ifosfamide\", \"useful in treatment of\", \"testicular cancers\"], [\"Encephalopathy\", \"reported in\", \"10-40 % of patients receiving high-dose IV ifosfamide\"], [\"electroencephalogram (EEG)\", \"role is\", \"early detection of ifosfamide related encephalopathy\"], [\"electroencephalogram (EEG)\", \"role is\", \"management of ifosfamide related encephalopathy\"], [\"five patients\", \"admitted to\", \"MD Anderson Cancer Center\"], [\"five patients\", \"developed\", \"ifosfamide related acute encephalopathy\"], [\"symptoms of encephalopathy\", \"experienced\", \"soon after receiving ifosfamide\"], [\"Two patients\", \"developed\", \"generalized convulsions\"], [\"one patient\", \"developed\", \"continuous non-convulsive status epilepticus (NCSE)\"], [\"Initial EEG\", \"showed\", \"epileptiform discharges in three patients\"], [\"Initial EEG\", \"showed\", \"run of triphasic waves in one patient\"], [\"Initial EEG\", \"showed\", \"moderate degree diffuse generalized slowing\"], [\"Initial EEG\", \"showed\", \"Mixed pattern with the presence of both sharps and triphasic waves\"], [\"Repeat EEGs\", \"showed marked improvement\", \"within 24h of symptom onset\"], [\"marked improvement on repeat EEGs\", \"correlated with\", \"clinical improvement\"], [\"Severity of ifosfamide related encephalopathy\", \"correlates with\", \"EEG changes\"]]",
      "Dose - dependent neurotoxicity of high - dose busulfan in children : a clinical and pharmacological study .|Busulfan is known to be neurotoxic in animals and humans , but its acute neurotoxicity remains poorly characterized in children .|We report here a retrospective study of 123 children ( median age , 6 . 5 years ) receiving high - dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors , brain tumors excluded .|Busulfan was given p . o . , every 6 hours for 16 doses over 4 days .|Two total doses were consecutively used : 16 mg / kg , then 600 mg / m2 .|The dose calculation on the basis of body surface area results in higher doses in young children than in older patients ( 16 to 28 mg / kg ) .|Ninety - six patients were not given anticonvulsive prophylaxis ; 7 ( 7 . 5 % ) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing .|When the total busulfan dose was taken into account , there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg / kg ( 1 of 57 , 1 . 7 % ) and patients under 600 mg / m2 ( 6 of 39 , 15 . 4 % ) ( P less than 0 . 02 ) .|Twenty - seven patients were given a 600 - mg / m2 busulfan total dose with continuous i . v .|infusion of clonazepam ; none had any neurological symptoms .|Busulfan levels were measured by a gas chromatographic - mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg / m2 busulfan with clonazepam : busulfan cerebrospinal fluid : plasma ratio was 1 . 39 .|This was significantly different ( P less than 0 . 02 ) from the cerebrospinal fluid : plasma ratio previously defined in children receiving a 16 - mg / kg total dose of busulfan .|This study shows that busulfan neurotoxicity is dose - dependent in children and efficiently prevented by clonazepam .|A busulfan dose calculated on the basis of body surface area , resulting in higher doses in young children , was followed by increased neurotoxicity , close to neurotoxicity incidence observed in adults .|Since plasma pharmacokinetic studies showed a faster busulfan clearance in children than in adults , this new dose may approximate more closely the adult systemic exposure obtained after the usual 16 - mg / kg total dose , with potential inferences in terms of anticancer or myeloablative effects .|The busulfan dose in children and infants undergoing bone marrow transplantation should be reconsidered on the basis of pharmacokinetic studies .": " Here are the relationships I extracted from the prompt:\n\n[[\"Busulfan\", \"is known to be\", \"neurotoxic\"], [\"Busulfan\", \"remains poorly characterized in\", \"children\"], [\"study\", \"of\", \"123 children\"], [\"children\", \"receiving\", \"high - dose busulfan\"], [\"busulfan\", \"given\", \"p.o.\"], [\"Busulfan\", \"given\", \"every 6 hours\"], [\"Busulfan\", \"given for\", \"16 doses\"], [\"Busulfan\", \"given over\", \"4 days\"], [\"Two total doses\", \"were\", \"16 mg / kg\"], [\"Two total doses\", \"were\", \"600 mg / m2\"], [\"dose calculation\", \"on the basis of\", \"body surface area\"], [\"dose calculation\", \"results in\", \"higher doses in young children\"], [\"96 patients\", \"were not given\", \"anticonvulsive prophylaxis\"], [\"7 ( 7 . 5 % )\", \"developed\", \"seizures\"], [\"seizures\", \"during\", \"the 4 days of the busulfan course\"], [\"seizures\", \"within\", \"24 h after the last dosing\"], [\"significant difference\", \"in terms of\", \"neurotoxicity incidence\"], [\"patients under 16 mg / kg\", \"and\", \"patients under 600 mg / m2\"], [\"Twenty - seven patients\", \"were given\", \"600 - mg / m2 busulfan total dose\"], [\"Twenty - seven patients\", \"were given\", \"continuous i.v. infusion of clonazepam\"], [\"none\", \"had\", \"any neurological symptoms\"], [\"Busulfan levels\", \"measured by\", \"gas chromatographic - mass spectrometry assay\"], [\"busulfan\", \"in\", \"the plasma\"], [\"busulfan\", \"in\", \"the cerebrospinal fluid\"], [\"busulfan cerebrospinal fluid : plasma ratio\", \"was\", \"1.39\"], [\"ratio\", \"in\", \"9 children\"], [\"ratio\", \"under\", \"600 mg / m2 busulfan\"], [\"ratio\", \"under\", \"clonazepam\"], [\"ratio\", \"significantly different from\", \"ratio previously defined\"], [\"ratio previously defined\", \"in\", \"children receiving\"], [\"ratio previously defined\", \"in\", \"16 - mg / kg total dose of busulfan\"], [\"This study\", \"shows\", \"busulfan neurotoxicity is dose-dependent in children\"], [\"busulfan neurotoxicity\", \"efficiently prevented by\", \"clonazepam\"], [\"busulfan dose calculated on body surface area\", \"resulting in\", \"higher doses in young children\"], [\"new dose\", \"followed by\", \"increased neurotoxicity\"], [\"neurotoxicity incidence\", \"close to\", \"neurotoxicity incidence observed in adults\"], [\"plasma pharmacokinetic studies\", \"showed\", \"faster busulfan clearance in children\"], [\"faster clearance\", \"than in\", \"adults\"], [\"new dose\", \"may approximate\", \"adult systemic exposure\"], [\"adult systemic exposure\", \"obtained after\", \"usual 16 - mg / kg total dose\"], [\"dose\", \"in children and infants\", \"undergoing bone marrow transplantation\"], [\"dose\", \"should be reconsidered on\", \"pharmacokinetic studies\"]]",
      "Impaired fear recognition in regular recreational cocaine users .|INTRODUCTION : The ability to read facial expressions is essential for normal human social interaction .|The aim of the present study was to conduct the first investigation of facial expression recognition performance in recreational cocaine users .|MATERIALS AND METHODS : Three groups , comprised of 21 cocaine naive participants ( CN ) , 30 occasional cocaine ( OC ) , and 48 regular recreational cocaine ( RC ) users , were compared .|An emotional facial expression ( EFE ) task consisting of a male and female face expressing six basic emotions ( happiness , surprise , sadness , anger , fear , and disgust ) was administered .|Mean percent accuracy and latencies for correct responses across eight presentations of each basic emotion were derived .|Participants were also assessed with the \" Eyes task \" to investigate their ability to recognize more complex emotional states and the Symptom CheckList - 90 - Revised to measure psychopathology .|RESULTS : There were no group differences in psychopathology or \" eyes task \" performance , but the RC group , who otherwise had similar illicit substance use histories to the OC group , exhibited impaired fear recognition accuracy compared to the OC and CN groups .|The RC group also correctly identified anger , fear , happiness , and surprise , more slowly than CN , but not OC participants .|The OC group was slower than CN when correctly identifying disgust .|The selective deficit in fear recognition accuracy manifested by the RC group can not be explained by the subacute effects of cocaine , or ecstasy , because recent and less recent users of these drugs within this group were similarly impaired .|Possible parallels between RC users and psychopaths with respect to impaired fear recognition , amygdala dysfunction , and etiology are discussed .": " Based on the prompt, here are the extracted entity relationships:\n\n[[\"recreational cocaine users\", \"have\", \"impaired fear recognition\"], [\"recreational cocaine users\", \"exhibit\", \"impaired fear recognition accuracy compared to the OC and CN groups\"], [\"ability to read facial expressions\",\"is essential for\",\"normal human social interaction\"], [\"present study\",\"was to conduct\",\"the first investigation of facial expression recognition performance in recreational cocaine users\"], [\"Three groups\", \"comprised of\", \"21 cocaine naive participants (CN), 30 occasional cocaine (OC), and 48 regular recreational cocaine (RC) users\"], [\"Emotional facial expression (EFE) task\", \"consisting of\", \"a male and female face expressing six basic emotions\"], [\"basic emotions\", \"include\", \"happiness, surprise, sadness, anger, fear, and disgust\"], [\"Participants\", \"were also assessed with\", \"the \\\"Eyes task\\\"\"], [\"Participants\", \"were also assessed with\", \"the Symptom CheckList - 90 - Revised\"], [\"RC group\", \"exhibited\", \"impaired fear recognition accuracy compared to the OC and CN groups\"], [\"RC group\", \"correctly identified\", \"anger, fear, happiness, and surprise, more slowly than CN\"], [\"OC group\", \"was\", \"slower than CN when correctly identifying disgust\"], [\"selective deficit in fear recognition accuracy\", \"manifested by\", \"the RC group\"], [\"impaired fear recognition manifested by RC group\", \"can not be explained by\", \"the subacute effects of cocaine, or ecstasy\"], [\"Possible parallels\", \"between\", \"RC users and psychopaths with respect to impaired fear recognition, amygdala dysfunction, and etiology\"],[\"amygdala\", \"related to\", \"dysfunction\"], [\"amygdala dysfunction\", \"related to\", \"impaired fear recognition\"],[\"impaired fear recognition\", \"common to\", \"RC users and psychopaths\"]]",
      "Mania associated with fluoxetine treatment in adolescents .|Fluoxetine , a selective serotonin reuptake inhibitor , is gaining increased acceptance in the treatment of adolescent depression .|Generally safe and well tolerated by adults , fluoxetine has been reported to induce mania .|The cases of five depressed adolescents , 14 - 16 years of age , who developed mania during pharmacotherapy with fluoxetine , are reported here .|Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention - deficit hyperactivity disorder and affective instability ; major depression with psychotic features ; a family history of affective disorder , especially bipolar disorder ; and a diagnosis of bipolar disorder .|Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents .": " Here are the relationships extracted from the prompt:\n\n[[\"Mania\", \"associated with\", \"fluoxetine treatment\"], [\"Fluoxetine\", \"is a\", \"selective serotonin reuptake inhibitor\"], [\"Fluoxetine\", \"is gaining acceptance in treatment of\", \"adolescent depression\"], [\"fluoxetine\", \"has been reported to induce\", \"mania\"], [\"five depressed adolescents\", \"developed\", \"mania\"], [\"five depressed adolescents\", \"during pharmacotherapy with\", \"fluoxetine\"], [\"attention deficit hyperactivity disorder\", \"is a risk factor for developing\", \"mania\"], [\"affective instability\", \"is a risk factor for developing\", \"mania\"], [\"major depression with psychotic features\", \"is a risk factor for developing\", \"mania\"], [\"family history of affective disorder\", \"is a risk factor for developing\", \"mania\"], [\"family history of\", \"bipolar disorder\", \"is a risk factor for developing\", \"mania\"], [\"bipolar disorder\", \"is a risk factor for developing\", \"mania\"], [\"Further study\", \"is needed to determine\", \"optimal dosage of fluoxetine\"], [\"Further study\", \"is needed to identify\", \"risk factors\"], [\"risk factors\", \"increase\", \"individual vulnerability to fluoxetine induced mania\"]]"
}